Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 25, 2012

Bio-Rad and Myriad RBM Collaborate to Commercialize Multiplex Biomarker Kits

  • Bio-Rad Laboratories and Myriad RBM have partnered to develop and distribute immunoassay kits. The agreement combines Myriad RBM's menu of multiplexed immunoassays with Bio-Rad's global commercial distribution capabilities. For research purposes, Myriad RBM grants Bio-Rad exclusive distribution rights to a catalog of quantitative multiplexed immunoassays currently available to run on the Bio-Plex® 200, Bio-Plex® 3D, and Bio-Plex® MAGPIX™ instruments.

    In an effort to optimize treatment and improve patient care, the partnership allows Bio-Rad and Myriad RBM to help researchers and clinicians develop biomarker profiles that may predict, detect, or monitor disease progression. Researchers’ needs for multiplex testing of samples with very low volumes when studying toxicology, oncology, immunology, cardiovascular, and other diseases are addressed by Myriad RBM’s assays. The new assays expand Bio-Rad's current suite of assays.



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »